Concomitant Nitrofurantoin-Induced Autoimmune Hepatitis and Interstitial Lung Disease

Andreia Carvalho de Matos, Cristiane Pais Macedo, Patrícia Afonso Mendes, Maria Augusta Cipriano, Artur Paiva, Adélia Simão

Internal Medicine Department, Coimbra Hospital and University Center, Coimbra, Portugal; University Clinic of Internal Medicine, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Pathology Department, Coimbra Hospital and University Center, Coimbra, Portugal; Flow Cytometry Unit, Coimbra Hospital and University Center, Coimbra, Portugal

Keywords
Autoimmune hepatitis · Nitrofurantoin toxicity · Interstitial pulmonary disease

Abstract
Antibiotics are known to cause adverse reactions, but multiple organ involvement associated with nonspecific symptoms can lead to a delay in diagnosis. A definitive correlation between each toxin and its effects is difficult to establish due to concomitant potential toxins in the circulation. This article highlights an uncommon case of concomitant nitrofurantoin-induced autoimmune hepatitis and lung fibrosis that fulfills the definitive clinical criteria for diagnosis, presenting histological, imagiological, and immunological evidence of nitrofurantoin-induced toxicity. It occurred in a 68-year-old woman with extended nitrofurantoin intake for urinary tract infection prophylaxis who presented with progressive exercise dyspnea and jaundice. Similar published cases are also reviewed in this article.

Hepatite autoimune e doença pulmonar intersticial induzidas por nitrofurantoína

Palavras Chave
Hepatite autoimmune · Toxicidade a nitrofurantoína · Doença pulmonar intersticial

Resumo
Os antibióticos são causas conhecidas de reações adversas, mas o envolvimento multiorgânico associado à sintomatologia inespecífica pode conduzir ao atraso diagnóstico. Devido às potenciais toxinas concomitantes em circulação, é muitas vezes difícil estabelecer uma correlação definitiva entre cada toxina e seus efeitos. Este artigo salienta um caso incomum de hepatite autoimune e fibrose pulmonar induzidas pela nitrofurantoína e que cumpre critérios definitivos de diagnóstico, apresentando-se dados histológicos, imagiológicos e imunológicos da toxicidade induzida pela nitrofurantoína. O caso ocorre numa mulher de 68 anos de idade, com
toma prolongada de nitrofurantoína como profilaxia de infecção urinária, e que se apresenta com dispneia de esforço progressiva e icterícia. O artigo faz ainda uma revisão de casos semelhantes publicados.

© 2021 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel

Introduction

Nitrofurantoin is a well-recognized drug with multiple adverse reactions. However, concomitant lung and hepatotoxicity is uncommon and has been reported in 10–18% of nitrofurantoin-associated hepatotoxicity series [1]. Nitrofurantoin-induced autoimmune hepatitis has a female predominance (85.5%), with 38.5% of cases occurring in elderly patients (>65 years) [2], and age is a particular risk factor for liver injury in chronic forms [3]. Liver biochemistry tests suggesting hepatocellular injury are the most frequent alterations (67–71%), but occasional cholestasis may be present [3, 4]. Liver biopsy often shows a pattern of chronic active hepatitis. In chronic cases, nuclear antibodies (80–82%), smooth muscle antibodies (55–73%), and lupus erythematosus cells (50%) were frequently presented [1, 5]. The authors present an uncommon and concomitant adverse reaction with a common drug.

Case Presentation

A 68-year-old immigrant Iranian woman was treated with nitrofurantoin 100 mg once daily for urinary tract infection prophylaxis from January 2017 to June 2019. In September 2019, after suspicion of urinary tract infection, she restarted nitrofurantoin at the same dose. From November to March 2020, she presented progressive exercise dyspnea, fatigue, member cramps, and irritating nocturnal cough. She started amoxicillin, clavulanic acid, and clarithromycin for a diagnosis of respiratory infection, without response. In April 2020, she began experiencing involuntary weight loss (7%), stopped statin, and started taking a red rice pill once a day. In June 2020, painless jaundice, mild itchiness, dark brown urine, and fecal acholia for the previous 3 weeks led to an internal medicine ward admission for additional investigation. Ten days prior to admission, amoxicillin and clarithromycin were prescribed after Helicobacter pylori identification. Some other courses of antibiotic and anti-inflammatory drugs were prescribed since 2017 (Fig. 1). Her medical records disclosed dyslipidemia and surgical hypothyroidism. There was no history of liver disease or alcohol or drug consumption. Physical examination showed an afebrile and normal-weight patient with sclerotic jaundice, pulmonary bilateral and inferior fine inspiratory crackles, normal peripheral rest oxygen saturation, and no abdominal portosystemic circulation, organomegaly, masses, pain, or ascites. Her cardiac and cutaneous examination was unremarkable and she had no encephalopathy, edema, or adenopathies. At this moment, after a high clinical suspicion, nitrofurantoin, amoxicillin, and clarithromycin were stopped.

Blood analysis disclosed hepatocellular liver injury (ALT/ALP ratio 11.3), hyperbilirubinemia (10.25 upper limit of normal), hypoalbuminemia (minimum 2.1 g/L), and slightly lower prothrombin (53%) with normal factor V and platelet values. ProBNP was normal. Severe vitamin D deficiency with secondary hyperparathyroidism was diagnosed, without vitamin B12 or B9 deficiency. Her ferritin value was 600 ng/mL (normal 30–300), with increased transferrin saturation (91%) but no detection of H63D, S65C, or C282Y HFE mutations. Electrophoresis showed gamma fraction polyclonal peak with IgG 35.79 g/L (normal 5.52–16.31). Seric autoimmunity unveiled a homogeneous pattern (AC1) antinuclear antibody titer of 1/640, but presence of other antibodies such as anti-ds-DNA, anti-histones, anti-SSA60, SSB, Sm, RNP, Sc170, JO1, anti-mitochondrial, pyruvate, anti-LKM, SLA/LP, LC-1, and smooth muscle antibodies was excluded. Until 2017, liver enzymes and autoimmunity panel were unremarkable. Acute or chronic viral hepatitis (A, B, C, and E) and other hepatotropic viruses (cytomegalovirus, herpesvirus, and Epstein-Barr virus) were also ruled out. Similarly, metabolic liver conditions were assessed, including alpha-1-antitrypsin deficiency, Wilson disease, and hemochromatosis. Lower limb electromyogram was normal. Biochemical urinary analysis, cytological examination, as well as bladder and kidney imaging did not show any alterations. Abdominal CT disclosed lobulated and heterogeneous liver tissue and a mild perihepatic effusion, without bile obstruction or expansive process. Liver biopsy (Fig. 2) supported the diagnosis of chronic hepatitis with typical autoimmune features: portal tract mononuclear cell inflammatory infiltrate, with mild plasmacytes and some eosinophils, severe interface hepatitis with focal emperipolesis, perivenular hepatocellular rosetting and ballooning, and ductular reaction. Severe panlobular bilirubinostasis, focal lobular necroinflammatory activity, and mild to moderate portal fibrosis (Masson trichrome) were also observed as well as focal perportal copper deposit (rhomadine). Biliary lesions, steatosis, iron deposit (Perls) and hyaline inclusions (PAS-D) were absent. High-resolution chest CT (Fig. 3) supported a previous radiologic hypothesis: bilateral inferior fibrosis. Despite a normal respiratory function test in December, a repeat evaluation in June disclosed moderate restrictive lung disease with mild reduced carbon monoxide diffusion. In bronchial fibroscopy, macrophage predominance, a low CD4/8 ratio, and unspecific lymph-hystiocitary inflammatory cells was observed, without neoplasia or infectious evidence (Pneumocystis jirovecii, bacteria, Mycobacteria, fungus, and cytomegalovirus). Echocardiography and electrocardiography were normal. In vitro lymphocyte transformation test disclosed, in the presence of nitrofurantoin, a mild increase in TCD4 cells expressing CD25 (IL-2 receptor α-subunit).

Considering the histological evidence and progressive liver dysfunction, prednisolone 1 mg/kg/day and calcium plus vitamin D supplementation were initiated. Corticoid therapy was complicated by hyperglycemia and cushingoid appearance. Therefore, the patient initiated azathioprine with further dose titration and prednisolone was tapered. Her thiopurine methyltransferase genotype was 1*1*, compatible with normal enzyme activity. After 6 months, the patient presented good tolerance to azathioprine, had no fatigue or cramps, and showed improved dyspnea although in-
Nitrofurantoin Toxicity

Fig. 1. Clinical course and timeline of nitrofurantoin intake and their relationship with liver enzymes alterations in ALT ULN/AF ULN ratio and total bilirubin (times ULN). * Normal values included liver function and enzymes, but also antinuclear antibodies and IgG evaluated in 2016. HP, *Helicobacter pylori* therapy (amoxicillin and macrolide); ULN, upper limit of normal.

Fig. 2. Liver biopsy. a Chronic hepatitis pattern of injury with portal-based fibrosis and dense inflammatory cell infiltrates composed of lymphocytes and plasma cells with severe periportal interface activity, hepatocyte rosettes (arrowhead), ductular reaction, and focal emperipolesis. Hematoxylin and eosin stain, ×100. b Perivenular necro-inflammatory activity with prominent mononuclear inflammation and bilirubinostasis with bile plugging of dilated canaliculi (arrowhead). Hematoxylin and eosin stain, ×200. c Acidophil body (individual necrotic hepatocyte). Hematoxylin and eosin stain, ×200.
terstitial lung fibrosis persisted in follow-up chest CT. Figure 1 summarizes the clinical and analytical evolution with normalization of ALT/AF ratio, total bilirubin, and liver function. IgG also reached normal values. According to the Naranjo Adverse Drug Reaction Probability Scale, this case fulfills definite causality for nitrofurantoin-associated liver toxicity.

Discussion and Conclusion

We present a case of definite causality of nitrofurantoin with autoimmune-like hepatitis, concurrent with interstitial lung disease. This is an uncommon combination of nitrofurantoin toxicity only described in a few publications and present in 10–18% of nitrofurantoin-associated hepatotoxicity series [1].

The Netherlands Centre for Monitoring of Adverse Reactions to Drugs stated that in 261 autoimmune hepatitis cases from 1963 to 1988 [4, 6], 24 (9.2%) were suspected to be drug-induced and >90% due to nitrofurantoin or minocycline-induced. Antibiotics were common hepatotoxicity-associated drugs following cytostatic and immunomodulatory therapy (17%) in a Portuguese database [4, 7]. According to European data, EudraVigilance [2], from a total of 7,868 cases of nitrofurantoin adverse reactions, where 0.8% were Portuguese reports, 740 (9.4%) had hepatobiliary disorders, which included autoimmune hepatitis in 78. However, most reactions were reported as acute or chronic unspecified liver injury, and therefore the underlying liver injury data are limited [2]. Further, potential concomitant toxins sometimes hamper a definitive relationship between drug and injury.

In our case, clarithromycin was a potential liver toxic, but it faults in temporal relation and typical liver injury pattern, which usually appears within the first 1–3 weeks and with a cholestatic hepatitis pattern [3]. Nitrofuranto-in-induced autoimmune hepatitis seems to have a female predominance (86–100%) [6], and 38.5% occur in elderly (patients >65 years) [2], with age acting as a possible risk factor for liver injury in chronic forms [3]. Liver biochemistry suggested hepatocellular injury pattern as the most frequent (67–71%), with occasional cholestasis [4, 6]. In chronic cases, nuclear antibodies (80–82%), smooth muscle antibodies (55–73%), and lupus erythematosus cells (50%) were frequently present [5, 6, 8]. It is believed that a breakdown product or nitrofurantoin itself that has been presented to class I HLA complex activates cytotoxic T cells, this with a pathogenic role in drug-induced liver injury [9]. On the other hand, nitrofurantoin-induced lung injury was reported in 28.5%, one-third with pulmonary fibrosis or interstitial lung disease [2], and the reason why nitrofurantoin affects the lungs remains unclear, but the ability to generate oxygen radicals and to cause lung injury seems to be one mechanism [10]. In our case a lymphocyte transformation test (Fig. 4) was additionally done but, nowadays, it does not have a definite role in the diagnosis of drug-induced lung disease [11] or in liver injury where data were not reproducible, except for isoniazid-associated liver injury [12].

We selected PubMed Central database articles focusing on published cases of concomitant nitrofurantoin-induced lung and liver disease, including adults with a pulmonary evaluation and liver biopsy (Table 1) [9, 13–18]. Data showed elderly women with prolonged nitrofurantoin use, where fatigue and respiratory symptoms (as dyspnea and dry cough) precede jaundice for weeks to months. Mild to moderate restrictive lung pattern with reduced diffusing lung capacity for carbon monoxide was frequent. As mentioned above, similar hepatocellular injury and serological profile were identified. Clinical and analytical recovery occurs in almost all patients after 1–2
months after drug withdrawal, but pulmonary dysfunction may persist. However, and after data revision, possible confounders may exist: undiagnosed or unreported concomitant organ toxicity, difficulty in establishing a definitive relationship between drug and toxicity, potential simultaneous toxic drugs, and a lack of medical practice in reporting drug reaction. The article highlights an uncommon concomitant liver and lung toxicity due to a common drug but with unspecified and unrecognized symptoms causing a delay in diagnosis.

**Learning Points**

1. Concomitant lung fibrosis and nitrofurantoin-induced autoimmune hepatitis is not commonly reported.
2. It is more frequent in elderly women with prolonged nitrofurantoin intake and respiratory symptoms preceding jaundice for weeks to months.
3. Restrictive lung pattern, hepatocellular injury, as well as nuclear and smooth muscle antibodies are frequent findings.
Table 1. Selected PubMed Central database articles focusing on concomitant nitrofurantoin-induced lung and autoimmune hepatitis; adults with pulmonary evaluation and liver biopsy were included [9, 13–18]

| Author                        | Sex/age, years | Months, dose, mg | Symptoms                                      | Onset | Chest image and/or LFT | Biopsy                                                                 | IgG and antibodies | AST (× ULN) | ALT/AF ratio | GGT (× ULN) | Bilirubin (× ULN) | Liver function | Corticoid | Follow-up          |
|-------------------------------|----------------|------------------|------------------------------------------------|-------|------------------------|----------------------------------------------------------------------|-------------------|-------------|---------------|-------------|-------------------|----------------|-----------|-------------------|
| Purohit et al. [13], 2012, New York | F/77            | 30               | dry cough, shortness of breath, weight loss, malaise | 2 months, 6 months | solid, semisolid, and ground-glass opacity extending to bilateral upper lung lobes; mild chronic interstitial mixed inflammation, rare histiocytes | chronic hepatitis; moderately active portal inflammation mainly of lymphocytes and conspicuous numbers of neutrophils and eosinophils; interface hepatitis; focal lobular inflammation | ND; ANA positive weekly | 14×         | ND (AF 6×)    | ND           | 1.8×             | ND             | PDN 60 mg/day | resolved (clinic) 1 month |
| Milić et al. [14], 2012, Serbia | F/77            | 6, 200/day       | breathlessness, nonproductive cough, fever, general weakness, nausea, weight loss, polyarthritis | 6 weeks, few months | ground-glass opacity and consolidations without significant fibrotic change; moderate restrictive ventilation CVF 55%; severe decrease in DLCO (47%) | severe acute chronic active hepatitis; lymphocytic and plasmacytic inflammatory infiltrate; portal tact and parenchyma disruption; ballooning of hepatocytes | 22 g/L; ANA (+++ speckled pattern); SMA (+) | 15×         | 1.5×          | 41.8×        | 6.8×             | ND; 29 g/L album | MPDN 80 mg/day | complete recovery (clinical and exam) 12 months |
| Kiang et al. [15], 2011, Colombia | F/57            | 18, 100/day      | fatigue, decrease in energy level, jaundice | 6 months, 2 weeks | interstitial lung disease, bilateral infiltrates | large zones of necrotic liver; extensive bile duct proliferation; acute portal inflammation; cholestasis | normal; normal | 47×         | 40–4×         | 7.3×          | 10.8×             | failure          | PDN 20 mg/day | lung transplant 2 years, stable, normal allograft function |
| Yakim et al., 1997, reported in Kiang et al. [15], 2011 | F/62            | 5, 200/day       | shortness of breath, dry cough | ND | bilateral fibrotic thickening and patchy alveolar infiltrations in both lungs | restrictive lung disease | chronic active hepatitis | ND; ANA; homogenously pattern; anti-histone 1:80; SMA 1/20 | 4×          | 5.2×          | 1.1×          | normal          | normal no symptoms, X-ray, and LFT resolved in 2 weeks; serologic test in 3 months |
| Peall and Hodges [16], 2007, New Zealand | F/72            | 15, 100–300/day  | breathlessness, upper abdominal discomfort and nausea | months | peripheral alveolar shadowing and fibrotic changes; impaired diffusion capacity of 0.70 mmol/min/kPa L | moderate lobular hepatitis characterized by zone 3 necrosis | ND; ANA | 15 g/L; ANA (diffuse, chromosome positive) 1:80; SMA 1/40 | 20×         | 16–4×         | 2.6×          | normal          | ND; normal albumin | PDN 40 mg/day; 8 weeks 2 years; no recurrence |
| Kiley et al. [9], 1988, Ireland | F/77            | 18, 100/day      | malaise, anorexia, cough, dyspnea, bilateral periting | 3 months, 1 month | fibrotic lung disease bilaterally (mid and lower zones); acute restrictive lung disease | marked acute and chronic inflammation on portal tracts; proliferation of biliary ducts, prominent piecemeal necrosis; some smaller bile ducts inflamed, fatty change, and marked hydropic change | ND; ANA | 4×          | 6.7×          | 2.2×          | normal          | normal no LFT normal; 6-month lung function did not recover at same rate |
| Reinhart et al. [17], 1992, Michigan | F/77            | 2, 100/day       | fatigue, malaise, weight loss, dry nonproductive cough, mild dyspnea | 1 month, 3 weeks | patch areas of increased densities at the right base and apex on X-ray; mild restrictive disease | moderate infiltration of portal fields by lymphocytes and plasma cells; acute inflammatory cells, and eosinophils; piece meal necrosis in many areas and mild fibrosis; severe chronic active hepatitis | ND; ANA (homogeneous) 1:60; SMA 1/40 | 6×          | 20–6×         | 8.0×          | normal          | normal no (resolving clinic) 10 days; LFT normalized slowly |
| Schattnier et al. [18], 1999, Israel | F/57            | 3                 | painless jaundice, dry cough, dyspnea on exertion, fatigue and anorexia | day, 6 weeks | emphysematous diffuse bilateral focal and linear infiltrate small mild pleural effusion, restrictive pattern | marked portal space expansion with fibrosis; extensive bile duct proliferation; mixed inflammatory architecture disturbed; hepatocyte enlargement; fatty changes; cholestasis; Kupffer cell hyperplasia; severe retraction and infiltrate | normal; ANA 2+3+; SMA 1+ | 29×         | 4.6×          | 7.6×          | normal          | increase in INR (17 s); 28 g/L albumin | PDN 40 mg/day | died of sepsis |

ANA, antinuclear antibodies; DLCO, carbon monoxide diffusion capacity; LFT, lung function test; MPDN, methylprednisolone; ND, nondefined; PDN, prednisolone; SMA, anti-smooth muscle antibodies; ULN, upper limit of normal.
Statement of Ethics

This case report was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The authors state that the subject gave her written informed consent for publication of her case, including publication of images.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

There are no funding sources to declare.

Author Contributions

All authors contributed equally to data acquisition, writing, and approval of the final version of the paper and agreed on all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

References

1. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988 May-Jun;8(3):599–606.
2. Base de dados europeia de notificações de reações adversas medicamentosas suspeitas. European Medicines Agency, EudraVigilance. 2020. Available from: https://dap.ema.europa.eu/analytics/saw.dll/PortalPages.
3. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Nitrofurantoin. Updated May 1, 2020.
4. de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, et al.; Drug-Induced Liver Injury Network. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol. 2017 Jan;15(1):1340–52.e7.
5. Sheringham JM, Fazio R, Zautom M, Arras E. Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease. Clin Pract. 2012 Oct;2(4):e83.
6. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010 Jun;51(6):2040–8.
7. Autoridade Nacional do Medicamento e Produtos de Saúde. I.P. Sistema Nacional de Farmacovigilância. Relatórios de análise periódica de dados. 2020. Available from: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-unidade-humano/farmacovigilancia/notificacao-de-ram/analisese_periodica_dados.
8. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stoltz A, Talwalkar J, et al.; United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun;148(7):1340–52.e7.
9. Kelly BD, Heneghan MA, Bennani F, Connolly CE, O’Gorman TA. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol. 1998 May;93(5):819–21.
10. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012 May;13(1):39.
11. Suzuki Y, Miwa S, Shirai M, Ohba H, Murakami M, Fujita K, et al. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Chest. 2008 Nov;134(5):1027–32.
12. Whritenour J, Ko M, Zong Q, Wang J, Tartaro K, Schneider P, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol. 2017 Dec;14(1):31–8.
13. Purohit T, Kaur K, Che C, Warshafsky S, Dworkin B. Nitrofurantoin-induced liver injury: a case report. Am J Gastroenterol. 2012 Oct;107:S407.
14. Milic R, Plavec G, Tufegdžić I, Tomic I, Sarac S, Loncarević O. Nitrofurantoin-induced immune-mediated lung and liver disease. Vojnosanit Pregl. 2012 Jun;69(6):536–40.
15. Kiang TK, Ford JA, Yoshida EM, Partovi N. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. Can J Hosp Pharm. 2011 Jul;64(4):262–70.
16. Peall AF, Hodges A. Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report. J Med Case Reports. 2007 Aug;1(1):59.
17. Reinhart HH, Reinhart E, Korlipara P, Peleman R. Combined nitrofurantoin toxicity to liver and lung. Gastroenterology. 1992 Apr;102(4 Pt 1):1396–9.
18. Schattner A, Von der Walde J, Kozak N, Sokolovskaya N, Knobler H. Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci. 1999 May;317(5):336–40.